Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849728 | 0.82 | CYP2C9 (0.36) | — | |
| SCHEMBL4057718 | 0.76 | PKM (0.41) | PKMALDH1A1HSD11B1PRMT5WDR77 | |
| SCHEMBL4057608 | 0.76 | PKM (0.52) | PKMALDH1A1NPC1RAB9AHSD11B1 | |
| SCHEMBL3844870 | 0.76 | PKM (0.56) | PKMALDH1A1NPC1RAB9AHSD11B1 | |
| SCHEMBL4055790 | 0.76 | CYP2C9 (0.41) | — | |
| SCHEMBL3850543 | 0.70 | PKM (0.50) | PKMALDH1A1NPC1RAB9AHSD11B1 | |
| SCHEMBL3841419 | 0.69 | PKM (0.48) | PKMALDH1A1NPC1RAB9AHSD11B1 | |
| SCHEMBL15858211 | 0.68 | PKM (0.64) | PKMALDH1A1NPC1RAB9AHSD11B1 | |
| SCHEMBL1150706 | 0.68 | PKM (0.64) | PKMALDH1A1NPC1RAB9AHSD11B1 | |
| SCHEMBL14791285 | 0.68 | PKM (0.64) | PKMALDH1A1NPC1RAB9AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030248-A1 | Ethynylphenylbiadamantane derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-2014636-A1 | Ethynylphenylbiadamantane derivatives | Daicel Chemical Industries, Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030248-A1 | Ethynylphenylbiadamantane derivatives | CHRNA5, CHRNE, ADRA1D | PKM 4221/4885ALDH1A1 1329/4885NPC1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.